

# Esther Conde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2832634/publications.pdf>

Version: 2024-02-01

13  
papers

455  
citations

1040056

9  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

761  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular diagnosis in non-small-cell lung cancer: expert opinion on <i>ALK</i> and <i>ROS1</i> testing. <i>Journal of Clinical Pathology</i> , 2022, 75, 145-153.	2.0	26
2	Clinical and economic impact of <i>ROS1</i> -testing™ strategy compared to a <i>no-ROS1</i> -testing™ strategy in advanced NSCLC in Spain. <i>BMC Cancer</i> , 2022, 22, 292.	2.6	2
3	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1500.	2.4	3
4	Screening for <i>ROS1</i> fusions in patients with advanced non-small cell lung carcinomas using the VENTANA <i>ROS1</i> (SP384) Rabbit Monoclonal Primary Antibody. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 437-444.	3.1	10
5	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. <i>Future Oncology</i> , 2021, 17, 4011-4025.	2.4	10
6	Assessment of a New <i>ROS1</i> Immunohistochemistry Clone (SP384) for the Identification of <i>ROS1</i> Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
7	Aligning digital CD8 <sup>+</sup> scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. <i>Histopathology</i> , 2018, 72, 270-284.	2.9	17
8	Identification of <i>ALK</i> , <i>ROS1</i> , and <i>RET</i> Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017, 63, 751-760.	3.2	62
9	Profile of Ventana <i>ALK</i> (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 707-713.	3.1	43
10	The anaplastic lymphoma kinase testing conundrum. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 161-163.	3.1	7
11	Accurate Identification of <i>ALK</i> Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. <i>PLoS ONE</i> , 2014, 9, e107200.	2.5	58
12	The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung. <i>PLoS ONE</i> , 2010, 5, e12209.	2.5	51
13	Molecular Context of the <i>EGFR</i> Mutations: Evidence for the Activation of <i>mTOR/S6K</i> Signaling. <i>Clinical Cancer Research</i> , 2006, 12, 710-717.	7.0	116